COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury

Tomas Luther, Sara Bülow-Anderberg, Anders Larsson, Sten Rubertsson, Miklos Lipcsey, Robert Frithiof, Michael Hultström, Tomas Luther, Sara Bülow-Anderberg, Anders Larsson, Sten Rubertsson, Miklos Lipcsey, Robert Frithiof, Michael Hultström

Abstract

Background: Acute kidney injury (AKI) is a syndrome of reduced glomerular filtration rate and/or reduced urine flow associated with mortality in corona virus disease 2019 (COVID-19). AKI is often associated with renal tissue damage, which may lead to chronic kidney disease. Biomarkers of tissue damage may identify patients of particular risk.

Methods: In a prospective observational study of 57 patients admitted to intensive care, AKI incidence and characteristics was evaluated according to KDIGO criteria and related to days after admission. Urinary albumin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule 1 (KIM-1) and Plasma Tissue Inhibitor of MetalloProteinase 2 (TIMP-2) were analysed in 52 patients at admission. The majority (n = 51, 89%) of patients developed AKI, and 27 (47%) patients had predominantly oliguric AKI where oliguria was more severe than plasma Creatinine increase. Severe oliguria within first 2 days after admission was common (n = 37, 65%), whereas stage 2 and 3 AKI due to Creatinine occurred later than day 2 in 67% (12/18) of cases. Renal replacement therapy was started in 9 (16%) patients, and 30-day mortality was 28%. Urinary biomarkers were increased in a majority of patients, but did not robustly predict KDIGO stage. Most patients had microalbuminuria, and severe albuminuria (albumin Creatinine ratio > 30 mg/mmol) was found in n = 9 (17%) patients.

Conclusions: A majority of patients with COVID-19 admitted to the ICU develop AKI. The functional deficit is often low urinary volume, and initial levels of biomarkers are generally increased without clear relation to final AKI stage.

Keywords: COVID-19; acute kidney injury; biomarkers; intensive care.

Conflict of interest statement

The authors have no conflicts of interest.

© 2020 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta.

Figures

Figure 1
Figure 1
Flow chart detailing patient inclusion and analysis strata participation in a prospective observational study of acute kidney injury (AKI) incidence and biomarker profile in patients admitted with severe COVID‐19 in a tertiary ICU at a University Hospital in Sweden
Figure 2
Figure 2
Cumulative incidence of acute kidney injury (AKI) as proportion of patients without AKI according different criteria by different stages in relation to ICU Days in 57 patients included in a prospective observational study of AKI incidence and biomarker profile in patients admitted with severe COVID‐19 in a tertiary ICU at a University Hospital in Sweden. Proportions are illustrated according to classification by (A) combined KDIGO criteria (B) KDIGO Creatinine criteria only and (C) KDIGO Urine Output criteria only (N = 53)

References

    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727‐733.
    1. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS‐CoV‐2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574‐1581.
    1. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in‐hospital death of patients with COVID‐19. Kidney Int. 2020;97:829‐838.
    1. Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid‐19 . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708‐1720.
    1. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid‐19 in New York City. N Engl J Med. 2020;382:2372‐2374.
    1. Hirsch JS, Ng JH, Ross DW, et al. Northwell C‐RC, Northwell Nephrology C‐RC. Acute kidney injury in patients hospitalized with COVID‐19. Kidney Int. 2020;98:209‐218.
    1. Fisher M, Neugarten J, Bellin E, et al. AKI in hospitalized patients with and without COVID‐19: a comparison study. J Am Soc Nephrol. 2020;31:2145‐2157.
    1. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS‐CoV‐2 spike glycoprotein. Cell. 2020;181:281‐292 e6.
    1. Pan X‐W, Xu D, Zhang H, Zhou W, Wang L‐H. Cui X‐g. Identification of a potential mechanism of acute kidney injury during the COVID‐19 outbreak: a study based on single‐cell transcriptome analysis. Intensive Care Med. 2020;46:1114‐1116.
    1. Ronco C, Reis T. Kidney involvement in COVID‐19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16:308‐310.
    1. Hultstrom M, von Seth M, Frithiof R. Hyperreninemia and low total body water may contribute to acute kidney injury in COVID‐19 patients in intensive care. J Hypertens. 2020;38:1613‐1614.
    1. Sohrabian A, Noraddin F, Flodin M, Fredricsson A, Larsson A. Particle enhanced turbidimetric immunoassay for the determination of urine cystatin C on Cobas c501. Clin Biochem. 2012;45:339‐344.
    1. Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol. 2008;3:665‐673.
    1. Xie Y, Wang Q, Wang C, Qi C, Ni Z, Mou S. High urinary excretion of kidney injury molecule‐1 predicts adverse outcomes in acute kidney injury: a case control study. Crit Care. 2016;20:286.
    1. Nisula S, Kaukonen K‐M, Vaara ST, et al. Incidence, risk factors and 90‐day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med. 2013;39:420‐428.
    1. Vaara ST, Parviainen I, Pettila V, et al. Association of oliguria with the development of acute kidney injury in the critically ill. Kidney Int. 2015;89:200‐208.
    1. Vincent J‐L, Ferguson A, Pickkers P, et al. The clinical relevance of oliguria in the critically ill patient: analysis of a large observational database. Crit Care. 2020;24:171‐271.
    1. Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G. Classifying AKI by urine output versus serum creatinine level. J Am Soc Nephrol. 2015;26:2231‐2238.
    1. Md Ralib A, Pickering JW, Shaw GM, Endre ZH. The urine output definition of acute kidney injury is too liberal. Crit Care. 2013;17:R112.
    1. Panitchote A, Mehkri O, Hastings A, et al. Factors associated with acute kidney injury in acute respiratory distress syndrome. Ann Intensive Care. 2019;9:74.
    1. Tornblom S, Nisula S, Petaja L, et al. Urine NGAL as a biomarker for septic AKI: a critical appraisal of clinical utility‐data from the observational FINNAKI study. Ann Intensive Care. 2020;10:51.
    1. Bhatraju PK, Zelnick LR, Herting J, et al. Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy. Am J Respir Crit Care Med. 2019;199:863‐872.
    1. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394:1949‐1964.
    1. Ostermann M, McCullough PA, Forni LG, et al. Kinetics of urinary cell cycle arrest markers for acute kidney injury following exposure to potential renal insults. Crit Care Med. 2018;46:375‐383.
    1. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR. Neutrophil gelatinase‐associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010;36:1333‐1340.
    1. Pei G, Zhang Z, Peng J, et al. renal involvement and early prognosis in patients with COVID‐19 pneumonia. J Am Soc Nephrol. 2020;31:1157‐1165.
    1. James MT, Pannu N, Hemmelgarn BR, et al. Derivation and external validation of prediction models for advanced chronic kidney disease following acute kidney Injury. JAMA. 2017;318:1787‐1797.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere